期刊文献+

人血浆中苯巴比妥、拉莫三嗪、奥卡西平及其单羟基代谢物的HPLC测定 被引量:9

Determination of Phenobarbital, Lamotrigine, Oxcarbazepine and Monohydroxycarbazepine in Human Plasma by HPLC
下载PDF
导出
摘要 建立了HPLC法同时测定人血浆中苯巴比妥、拉莫三嗪、奥卡西平及其代谢物单羟奥卡两平浓度。以氯唑沙宗为内标,血浆样品以蛋白沉淀法处理。采用XDB-C18柱,流动相为甲醇-0.1%三氟乙酸(38:62)。双波长双通道检测,分别在215nm测定苯巴比妥和单羟奥卡西平,240nm测定拉莫三嗪和奥卡西平。4种药物的线性范围分别是5~100、1~50、0.5~50、2~100μg/ml。平均方法回收率分别为101.3%、100.7%、96.7%和101.5%。 A HPLC method was established for the simultaneous determination of phenobarbital, lamotrigine, oxcarbazepine and monohydroxycarbazepine in human plasma. The analytes were extracted by protein precipitation, using chlorzoxazone as internal standard. A XDB-C18 column was used with the mobile phase of methanol-0.1% triflouroacetic acid (38:62). Phenobarbital and monohydroxycarbazepine were detected at the wavelength of 215nm, while lamotrigine and oxcarbazepine at 240 nm. The calibration curves were linear in the ranges of 5 - 100, 1 - 50, 0.5 - 50 and 2 - 100μg/ml, respectively. The average recoveries were 101.3 %, 100.7 %, 96.7 % and 101.5 %, respectively.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2006年第6期415-417,共3页 Chinese Journal of Pharmaceuticals
关键词 苯巴比妥 拉莫三嗪 奥卡西平 单羟奥卡西平 高效液相色谱 测定 phenobarbital lamotrigine oxcarbazepine monohydroxycarbazepine HPLC determination
  • 相关文献

参考文献4

  • 1焦正,钟明康,施孝金,李中东,张静华,王宏图.抗癫癎药物监测[J].中国临床药学杂志,2004,13(6):386-389. 被引量:17
  • 2Bugamelli F,Sabbioni C,Mandrioli R,etal.Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction[J].Anal Chim Acta,2002,472 (1):1-10.
  • 3Franceschi L,Furlanut M.A simple method to monitor plasma concentrations of oxcarbazepine,carbamazepine,their main metabolites and lamotrigine in epileptic patients[J].Pharmacol Res,2005,51 (4):297-302.
  • 4Levert H,Odou P,Robert H.LC determination of oxcarbazepine and its active metabolite in human serum[J].J Pharm Biomed Anal,2002,28 (3-4):517-525.

二级参考文献14

  • 1Eadie MJ. Therapeutic drug monitoring-antiepileptic drugs[J]. Br J Clin Pharmacol, 2001,52(Suppl), 11.
  • 2Patsalos PN. Antiepileptic drug pharmacogenetics [J]. Ther Drug Monit, 2000,22(1) :127.
  • 3Ensom MH, Chang TK, Patel P. Pharmacogenetics the therapeutic drug monitoring of the future[J]. Clin Pharamcokinet, 2001,40(11):783.
  • 4Hadama A, Ieiri I, Morita T, et al. P-hydroxylation of phenobarbital:relationship to ( S )-mephenytoin hydroxylation ( CYP2C19 ) polymorphism[J]. Ther Drug Monit, 2001,23(2):115.
  • 5Pons G, Treluyer JM, Dimet J, et al. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates[J]. Ther Drug Monit, 2002,24(1) :9.
  • 6Wajima T, Fukumura K, Yano Y, et al. Prediction of human clearance from animal data and mnolecular structural parameters using multivariate regression analysis[J]. J Pharm Sci, 2002,91(12):2489.
  • 7Warner A, Privitera M, Bates D. Standards of laboratory practice:antiepileptic drug monitoring[J]. Clin Chem, 1998,44(5): 1085.
  • 8Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs[J]. Ther Drug Monit, 2003,25(3):347.
  • 9Hermida J, Tutor JC. How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10, 11-epoxide in serum samples[J]. Ther Drug Monit,2003,25(3):384.
  • 10Liu H, Delgado MR. Thearpeutic drug concentration monitoring using saliva samples focus on anticonvulsants[J]. Clin Pharmacokinet, 1999,36(6) :453.

共引文献16

同被引文献62

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部